

DEALS AND SUITS

COSCIENS Biopharma Inc. acquires Nualtis Corp.

On Sept. 10, 2026, BLG acted as lead counsel to COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) in connection with its acquisition of Nualtis Corp. from AtaiBeckley Inc. for a cash purchase price of US\$15 million (plus certain earn-out considerations), and a concurrent private placement of convertible debentures.

Nualtis is a Montréal-based specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies.

The multidisciplinary mandate involved public-company M&A and financing, intellectual property, regulatory, employment and tax considerations.

Read the news release: [COSCIENS acquires Nualtis Corp.](#)

The BLG team was led by Joe Zed (M&A / Corporate / Securities) and included Nicolas Nevins, Tamara Mitterer and Corbin Boes (M&A / Corporate / Securities); Benjamin Fuhrmann (Health / M&A); Rose Massicotte and Audrey-Pier Lachaine (Labour and Employment); Natasha Gulati (Intellectual Property); Joelle Kabouchi (Tax); Hélène Deschamps-Marquis and Élisabeth Lesage-Bigras (IT and Privacy); Raphael Roditi (Real Estate and Finance); and Claire Durocher (Environmental). BLG worked alongside K&L Gates as U.S. counsel to COSCIENS, and Alvarez & Marsal Canada as lead tax advisors.

BLG Team : [Joe Zed](#), [Nicholas Nevins](#), [Tamara Mitterer](#), [Corbin Boes](#), [Benjamin Fuhrmann](#), [Rose Massicotte](#), [Audrey-Pier Lachaine](#), [Natasha Gulati](#), [Joelle Kabouchi](#), [Hélène Deschamps Marquis](#), [Élisabeth Lesage-Bigras](#), [Raphael Roditi](#), [Claire R. Durocher](#)
